• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤位置不是早期非小细胞肺癌的独立预后因素。

Tumor location is not an independent prognostic factor in early stage non-small cell lung cancer.

机构信息

Department of Surgery, Washington University in St. Louis, St. Louis, Missouri 63110, USA.

出版信息

Ann Thorac Surg. 2010 Apr;89(4):1053-9. doi: 10.1016/j.athoracsur.2010.01.020.

DOI:10.1016/j.athoracsur.2010.01.020
PMID:20338306
Abstract

BACKGROUND

Conventional thoracic surgical teaching suggests a worse outcome for lower lobe lung cancers. It is unclear whether this is due to stage migration or whether lobar location is an independent negative prognostic factor.

METHODS

We performed a retrospective review of our institutional database of patients undergoing resection for pathologic stage I or stage II lung cancer between Jan 2000 and December 2006. Survival analysis was used to compare outcomes in various groups using the log-rank test. Logistic regression analysis was used to compare the primary dependent variables; age, size, and location of tumor (both laterality and lobe), histology (adenocarcinoma, squamous, large cell, or neuroendocrine and others) and type of resection (wedge, lobectomy or segmentectomy, and pneumonectomy).

RESULTS

A total of 841 patients met the inclusion criteria. The mean age of patients was 64.9 years, mean tumor size 3.3 cm, and, 144 patients had N1 disease. The three-year and five-year survivals for stage I tumors were 346 of 478 (72.4%) and 277 of 497 (55.7%), respectively. There was no difference in survival based upon lobar location. The three-year and five-year survivals for stage II tumors were 81 of 175 (46.3%) and 39 of 150 (26%), respectively, and lobar location did not influence survival. Logistic regression analysis showed that for stage I tumors increasing age and having undergone a pneumonectomy were associated with worse survival, and for stage II tumors increasing age and adenocarcinoma histology were associated with worse survival.

CONCLUSIONS

Tumor location within the lung does not predict survival in pathologic stage I/II non-small cell lung carcinoma. Increasing age, adenocarcinoma histology, and pneumonectomy as the resection may lead to worse long-term survival.

摘要

背景

传统的胸外科教学认为下叶肺癌的预后较差。目前尚不清楚这是由于分期迁移还是肺叶位置是独立的预后不良因素。

方法

我们对 2000 年 1 月至 2006 年 12 月期间接受病理 I 期或 II 期肺癌切除术的机构数据库进行了回顾性分析。使用对数秩检验对不同组的生存结果进行生存分析。使用逻辑回归分析比较主要依赖变量;年龄、肿瘤大小和位置(侧位和肺叶)、组织学(腺癌、鳞状细胞癌、大细胞癌或神经内分泌癌等)和切除类型(楔形切除术、肺叶切除术或节段切除术以及全肺切除术)。

结果

共有 841 例患者符合纳入标准。患者的平均年龄为 64.9 岁,平均肿瘤大小为 3.3cm,144 例患者有 N1 疾病。I 期肿瘤的 3 年和 5 年生存率分别为 478 例中的 346 例(72.4%)和 497 例中的 277 例(55.7%)。肺叶位置与生存率无差异。II 期肿瘤的 3 年和 5 年生存率分别为 175 例中的 81 例(46.3%)和 150 例中的 39 例(26%),肺叶位置也不影响生存率。逻辑回归分析表明,对于 I 期肿瘤,年龄增加和全肺切除术与生存率降低相关,而对于 II 期肿瘤,年龄增加和腺癌组织学与生存率降低相关。

结论

肺内肿瘤位置不能预测病理 I/II 期非小细胞肺癌的生存情况。年龄增加、腺癌组织学和全肺切除术可能导致长期生存较差。

相似文献

1
Tumor location is not an independent prognostic factor in early stage non-small cell lung cancer.肿瘤位置不是早期非小细胞肺癌的独立预后因素。
Ann Thorac Surg. 2010 Apr;89(4):1053-9. doi: 10.1016/j.athoracsur.2010.01.020.
2
Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection.肿瘤大小对非小细胞肺癌患者预后的影响:肺段切除术作为一种较小切除方式的作用
J Thorac Cardiovasc Surg. 2005 Jan;129(1):87-93. doi: 10.1016/j.jtcvs.2004.04.030.
3
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system.基于现行分期系统,肿瘤大小对 1A 期非小细胞肺癌解剖性肺切除术后结局的影响。
J Thorac Cardiovasc Surg. 2012 Feb;143(2):390-7. doi: 10.1016/j.jtcvs.2011.10.023. Epub 2011 Dec 9.
4
Survival Rates After Lobectomy, Segmentectomy, and Wedge Resection for Non-Small Cell Lung Cancer.非小细胞肺癌行肺叶切除术、节段切除术和楔形切除术的生存率。
Ann Thorac Surg. 2018 May;105(5):1483-1491. doi: 10.1016/j.athoracsur.2018.01.032. Epub 2018 Feb 17.
5
A propensity score matching analysis of survival following segmentectomy or wedge resection in early-stage lung invasive adenocarcinoma or squamous cell carcinoma.早期肺浸润性腺癌或鳞状细胞癌行肺段切除术或楔形切除术后生存情况的倾向评分匹配分析。
Oncotarget. 2016 Mar 22;7(12):13880-5. doi: 10.18632/oncotarget.7284.
6
Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer.影响I至IIIa期非小细胞肺癌切除术后十年生存率的因素。
J Thorac Cardiovasc Surg. 1999 Jan;117(1):32-6; discussion 37-8. doi: 10.1016/s0022-5223(99)70467-8.
7
Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis.肺叶切除术与节段切除术治疗 I 期非小细胞肺癌的生存比较:一项基于人群的分析。
Ann Thorac Surg. 2011 Dec;92(6):1943-50. doi: 10.1016/j.athoracsur.2011.05.091. Epub 2011 Oct 1.
8
Wedge resection verses lobectomy for stage 1 non-small-cell lung cancer.1期非小细胞肺癌楔形切除术与肺叶切除术的比较
Asian Cardiovasc Thorac Ann. 2013 Oct;21(5):566-73. doi: 10.1177/0218492312466861. Epub 2013 Jul 11.
9
Reassessment of Right Middle Lobe Lung Cancer: Comparison of Segments 4 and 5 Tumors.右中叶肺癌再评估:段 4 和段 5 肿瘤的比较。
Ann Thorac Surg. 2018 May;105(5):1543-1550. doi: 10.1016/j.athoracsur.2017.12.007. Epub 2018 Jan 9.
10
T1/T2 non-small-cell lung cancer treated by lobectomy: does tumor anatomic location matter?T1/T2 非小细胞肺癌行肺叶切除术治疗:肿瘤解剖位置是否重要?
J Surg Res. 2012 Oct;177(2):185-90. doi: 10.1016/j.jss.2012.05.022. Epub 2012 Jun 27.

引用本文的文献

1
Long-term results of middle lobectomy patients operated for non-small cell lung cancer.非小细胞肺癌患者行中叶切除术的长期结果。
Indian J Thorac Cardiovasc Surg. 2025 Apr;41(4):404-410. doi: 10.1007/s12055-024-01886-4. Epub 2025 Jan 16.
2
Tumor Location Is an Independent Prognostic Factor in Completely Resected Pathological Stage I Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.肿瘤位置是完全切除的病理I期非小细胞肺癌的独立预后因素:一项多中心回顾性研究
Cancers (Basel). 2024 Apr 27;16(9):1710. doi: 10.3390/cancers16091710.
3
Different nodal upstaging rates and prognoses for patients with clinical T1N0M0 lung adenocarcinoma classified according to the presence of solid components in the lung and mediastinal windows.
根据肺窗和纵隔窗中实性成分的存在情况对临床T1N0M0肺腺癌患者进行分类,其淋巴结分期上调率和预后各不相同。
J Thorac Dis. 2023 Jul 31;15(7):3612-3626. doi: 10.21037/jtd-23-18. Epub 2023 Jun 21.
4
Development and validation of nomograms to predict early death in non-small cell lung cancer patients with brain metastasis: a retrospective study in the SEER database.预测非小细胞肺癌脑转移患者早期死亡的列线图的开发与验证:一项基于SEER数据库的回顾性研究
Transl Cancer Res. 2023 Mar 31;12(3):473-489. doi: 10.21037/tcr-22-2323. Epub 2023 Mar 21.
5
Development and Validation of a Prognostic Nomogram for Lung Adenocarcinoma: A Population-Based Study.基于人群的肺腺癌预后列线图的建立和验证。
J Healthc Eng. 2022 Dec 10;2022:5698582. doi: 10.1155/2022/5698582. eCollection 2022.
6
Squamous cell carcinoma predicts worse prognosis than adenocarcinoma in stage IA lung cancer patients: A population-based propensity score matching analysis.在IA期肺癌患者中,鳞状细胞癌的预后比腺癌更差:一项基于人群的倾向评分匹配分析。
Front Surg. 2022 Aug 23;9:944032. doi: 10.3389/fsurg.2022.944032. eCollection 2022.
7
Survival rates of patients with tumors originating in different segments of the left upper lung in stage I to III non-small cell lung cancer.I至III期非小细胞肺癌中起源于左上肺不同节段的肿瘤患者的生存率。
Ann Transl Med. 2021 Oct;9(20):1590. doi: 10.21037/atm-21-5157.
8
The Prognostic Significance of the Histological Types in Patients With Nonsmall Cell Lung Cancer ≤2 cm.≤2厘米非小细胞肺癌患者组织学类型的预后意义
Front Surg. 2021 Oct 25;8:721567. doi: 10.3389/fsurg.2021.721567. eCollection 2021.
9
Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.定量分析肺部原发性肿瘤的空间分布,为局部晚期 NSCLC 开发新的预后生物标志物。
Sci Rep. 2021 Oct 22;11(1):20890. doi: 10.1038/s41598-021-00239-0.
10
Bone-Specific Metastasis Pattern of Advanced-Stage Lung Adenocarcinoma According to the Localization of the Primary Tumor.根据原发性肿瘤的位置确定晚期肺腺癌的骨转移模式。
Pathol Oncol Res. 2021 Sep 23;27:1609926. doi: 10.3389/pore.2021.1609926. eCollection 2021.